Astute Medical (San Diego, CA) a development-stage diagnostic company focused on the identification and validation of protein biomarkers that can test for hospital acquired acute conditions like sepsis, kidney injury and abdominal pain, closed a $26.5M Series B financing. Participants include Domain Associates, Delphi Ventures, Johnson & Johnson Development Corp. and De Novo Ventures.

Oxford Immunotec (United Kingdom) a commercial-stage molecular diagnostic company focused on an vitro test for the diagnosis of active and latent tuberculosis infection, closed a $26M Series D financing. Participants include New Leaf Venture Partners, Kaiser Permanente Ventures, Clarus Ventures, Wellington Partners, National Technology Enterprises Company, Spark Ventures, DFJ Esprit, Oxford University and Dow Chemical.

Aureon Laboratories (New York, NY) a commercial-stage diagnostic company focused on prognostic assays for prostate cancer and PSA, closed a $7M Series D financing. Participants have included Atlas Venture, New Leaf Venture Partners, Sprout Group and Pfizer.

Oxford Nanopore Technologies (United Kingdom) a development-stage medical device company focused on DNA sequencing via an electronic, label-free analysis of single molecule platform, closed a $28M Series C financing. Participants include Lansdowne Partners, IP Group, Invesco Perpetual and Illumina.

Rapid Diagnostek (Hudson, WI) a development-stage medical device company focused on vitro diagnostics using radio frequency phase shift technology for virus detection in fluid samples, closed a $4M Series B financing. Participants include Peak Ridge Capital.

Saladax Biomedical (Bethlehem, PA) a commercial stage developer of 5-FU diagnostic assays for the oncology market, closed an $8.4M Series B financing. Participants include Excel Venture Management, Golden Seeds, Ben Franklin Technology Partners and Life Sciences Greenhouse of Central Pennsylvania.

Nodality (San Francisco, CA) a development-stage molecular diagnostics company focused on hematological malignancies and autoimmune disorders, closed a $15.5M Series D financing. Participants include Pfizer Venture Investments, Laboratory Corp of America Holdings, Kleiner Perkins Caufield & Byers, Maverick Capital and TPG Growth.

BioBehavioral Diagnostics (Westford, MA) a commercial-stage diagnostics company focused on the Quotient™ ADHD System for the objective and accurate assessment of attention-deficit hyperactivity disorder, closed a $10M Series B financing. Participants include Sevin Rosen Funds and Tullis Health Investors.

Intuity Medical (Sunnyvale, CA) a clinical-stage diagnostic device company focused on all-in-one blood sample collection and glucose analysis, closed a Series D financing. Participants include Venrock, Emergent Medical Partners, Investor Growth Capital, Thomas McNerney and Partners, U.S. Venture Partners and Versant Ventures.

On-Q-lty (Waltham, MA) a development stage molecular diagnostics company incorporating microfluidics and biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors, closed a $5M Series A financing, bringing the total round to $26M. Participants include Atlas Venture, Mohr Davidow Ventures, Bessemer Venture Partners, Physic Ventures and Northgate Capital.
Note: [...]